Drug
Catumaxomab clinical trials
Also written Removab.
- studies test it
- 16
- open now
- 0
- in phase 3
- 2
- first study started
- 2004
How studies write it
Studies that test it under each name
Name
Brand
Combined with it in one product
Studies by the year they started
16 studies that test it; most in 2006 (3)
| Year | Studies |
|---|---|
| 2004 | 2 |
| 2006 | 3 |
| 2007 | 2 |
| 2009 | 1 |
| 2010 | 1 |
| 2011 | 2 |
| 2012 | 1 |
| 2013 | 1 |
| 2020 | 2 |
| 2021 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 3
- Phase 2
- 13
- Phase 3
- 2
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 11 · Other 5
Neovii Biotech (8) · LintonPharm Co.,Ltd. (2) · Lindis Biotech GmbH (1) · AIO-Studien-gGmbH (1) · Grupo Español de Investigación en Cáncer de Ovario (1) · JSehouli (1) · AGO Study Group (1) · Gustave Roussy, Cancer Campus, Grand Paris (1)
Often tested with
Tested in the same studies.
Fluorouracil (1) · Leucovorin (1) · Oxaliplatin (1) · Docetaxel (1)
Studies
Open first, then newest update. How each study uses catumaxomab is read from its arms, and is right about nine times in ten.
Testing it · 16
- Investigation of Safety and Tolerability of Catumaxomab in Patients With NMIBCCompletedPhase 1Lindis Biotech GmbHNCT04819399Written as Catumaxomab
- Catumaxomab in Patients With Non-Muscle-Invasive Bladder Cancer Who Have Failed or Are Intolerant to BCG VaccineStatus unknownPhase 1/2LintonPharm Co.,Ltd.NCT04799847Written as Catumaxomab
- Comparing the Efficacy and Safety of Intra-peritoneal Infusion of Catumaxomab and Treatment of Investigator Choice in Patients With Advanced Gastric Carcinoma With Peritoneal MetastasisStatus unknownPhase 3LintonPharm Co.,Ltd.NCT04222114Written as Catumaxomab
- Study of the Trifunctional Antibody Catumaxomab to Treat Recurrent Symptomatic Malignant AscitesCompletedPhase 2Neovii BiotechNCT00326885Written as catumaxomab
- Catumaxomab for Treatment of Peritoneal Carcinomatosis in Patients With Gastric AdenocarcinomasCompletedPhase 2AIO-Studien-gGmbHNCT01504256Written as catumaxomab, Fluorouracil, leucovorin, oxaliplatin, docetaxel
- Treatment of Gastric Peritoneal Carcinomatosis by Association of Complete Surgical Resection of the Lesions and Intraperitoneal Immunotherapy Using CatumaxomabTerminatedPhase 2Gustave Roussy, Cancer Campus, Grand ParisNCT01784900Written as Catumaxomab 100µg
- Catumaxomab as a Consolidation Therapy in Patients With Ovarian Cancer in Second or Third Clinical Disease RemissionCompletedPhase 2Grupo Español de Investigación en Cáncer de OvarioNCT01246440Written as Catumaxomab
- Feasibility and Clinical Activity of Initial Intraperitoneal Catumaxomab Followed by Chemotherapy in Patients With Recurrent Ovarian CancerCompletedPhase 2JSehouliNCT01815528Written as Catumaxomab
- Phase II Study With Catumaxomab in Patients With Gastric Cancer After Neoadjuvant CTx and Curative ResectionCompletedPhase 2Neovii BiotechNCT00464893Written as Catumaxomab
- A Open Label, Dose Escalating Study to Evaluate the Safety and Tolerability of Ascending Intravenous (i.v.) Doses of Catumaxomab in Epithelial Cancer PatientsTerminatedPhase 1Neovii BiotechNCT01320020Written as catumaxomab
- Safety Study of Second Intraperitoneal (I.P.) Infusion Cycle of Catumaxomab in Patients With Malignant AscitesCompletedPhase 2Neovii BiotechNCT01065246Written as catumaxomab
- Phase II Study of the Trifunctional Antibody Catumaxomab Administered Intra- and Postoperatively in Patients With Ovarian CancerCompletedPhase 2Neovii BiotechNCT00563836Written as Catumaxomab
- Safety and Efficacy Study of Catumaxomab to Treat Ovarian Cancer After a Complete Response to ChemotherapyCompletedPhase 2Neovii BiotechNCT00377429Written as catumaxomab
- Study in EpCAM Positive Patients With Symptomatic Malignant Ascites Using Removab Versus an Untreated Control GroupCompletedPhase 2/3Neovii BiotechNCT00836654Written as Catumaxomab (Removab)
- Safety and Efficacy Study With Catumaxomab in Patients After Curative Resection of a Gastric AdenocarcinomaCompletedPhase 2Neovii BiotechNCT00352833Written as catumaxomab
- Randomized, Multicenter, 2-Dose Level. Open-Label, Phase IIa Study With the Intraperitoneally Infused Trifunctional Bispecific Antibody Removab(TM) (Anti-EpCAM x Anti-CD3) to Select the Better Dose Level in Platinum Refractory Epithelial Ovarian Cancer PatientsCompletedPhase 2AGO Study GroupNCT00189345Written as anti-EpCAM x anti-CD3 (removab)
Given in every arm · 1 — catumaxomab is usual care beside what is tested
Codes
What other systems call catumaxomab · ClinicalTrials.gg INT005150
- MeSH (NLM) C522419catumaxomabConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) M2HPV837HOCATUMAXOMABConfirmed FDA, NLM, Wikidata
- Wikidata Q408155catumaxomabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C62445CatumaxomabOne source FDA
- DrugBank DB06607One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C522419 | catumaxomab | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | M2HPV837HO | CATUMAXOMAB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q408155 | catumaxomab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C62445 | Catumaxomab | One source FDA |
| DrugBank | DB06607 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.